Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 17/20 | 0.67 |
| ▸ | CPT2 | P23786 | 10/20 | 0.54 |
| ▸ | CPT1B | Q92523 | 7/20 | 0.54 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2307175 | 1.00 | CPT1A (0.67) | CPT1ACPT2CPT1BNTMT1GPR119 | |
| SCHEMBL2306593 | 0.86 | CPT1A (0.64) | CPT1ACPT2CPT1BGPR119 | |
| SCHEMBL2306585 | 0.86 | CPT1A (0.64) | CPT1ACPT2CPT1BGPR119 | |
| SCHEMBL2310187 | 0.85 | CPT1A (0.62) | CPT1ACPT2CPT1BGPR119 | |
| SCHEMBL2310181 | 0.85 | CPT1A (0.62) | CPT1ACPT2CPT1BGPR119 | |
| SCHEMBL2307483 | 0.84 | CPT1A (0.67) | CPT1ACPT2CPT1B | |
| SCHEMBL2307492 | 0.84 | CPT1A (0.67) | CPT1ACPT2CPT1B | |
| SCHEMBL2308070 | 0.83 | CPT1A (0.69) | CPT1ACPT2CPT1B | |
| SCHEMBL2308064 | 0.83 | CPT1A (0.69) | CPT1ACPT2CPT1B | |
| SCHEMBL28814072 | 0.83 | PRMT5 (0.55) | CPT1AGPR119GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039487-B2 | Piperidine-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2155738-B1 | PIPERIDINE-AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT2 3/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.